Previous studies have demonstrated that a peripheral corticotropin releasing factor (PCRF), which possesses CRF-like immunological and biological activity, is released from injured tissue during inflammation. Additional studies have demonstrated that synthetic CRF possesses potent antinociceptive and anti-inflammatory activity when injected directly into inflamed tissue. However, there is a gap in knowledge regarding the identity and regulation of release of peripheral CRF and regarding the mechanism(s) of action for the antinociceptive and anti-inflammatory effects of synthetic CRF. The objectives of this proposal will 1) identify the peripheral origin of CRF released during inflammation; 2) characterize the regulation of peripheral CRF release; 3) determine the effects of CRF on modulating the peripheral release of markers of primary afferents (immunoreactive substance P, CGRP), sympathetic fibers (immunoreactive NPY) and leukocytes (immunoreactive LTB4 and beta-endorphin); and 4) determine whether CRF-induced modulation of primary afferents, sympathetics or leukocytes contributes to its mechanism of action. Samples of PCRF and inflammatory mediators will be collected by subcutaneous placement of microdialysis probes into carrageenan-inflamed hindpaws of rats. The PCRF will be compared to synthetic CRF for its physicochemical similarity (HPLC elution profile, protease and oxidation susceptibility) and quantitated for CRF-like immunoreactivity (using a CRF radioimmunoassay) and CRF-like biological activity (using release of immunoreactive beta-endorphin from pituitary cultures). Levels of immunoreactive substance P, CGRP, NPY, LTB4 and beta-endorphin will be measured by previously validated radioimmunoassays. Collectively, this research proposal will evaluate the hypothesis of a new peripheral neuroendocrine axis, in which the process of inflammation leads to the local release and actions of an antinociceptive/anti-inflammatory peptide, CRF.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29DE009860-03
Application #
2130902
Study Section
Neurological Sciences Subcommittee 1 (NLS)
Project Start
1992-04-01
Project End
1997-03-31
Budget Start
1994-04-01
Budget End
1995-03-31
Support Year
3
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Dentistry
Type
Schools of Dentistry
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Ulrich-Lai, Y M; Flores, C M; Harding-Rose, C A et al. (2001) Capsaicin-evoked release of immunoreactive calcitonin gene-related peptide from rat trigeminal ganglion: evidence for intraganglionic neurotransmission. Pain 91:219-26
Kehl, L J; Trempe, T M; Hargreaves, K M (2000) A new animal model for assessing mechanisms and management of muscle hyperalgesia. Pain 85:333-43
Goodis, H E; Bowles, W R; Hargreaves, K M (2000) Prostaglandin E2 enhances bradykinin-evoked iCGRP release in bovine dental pulp. J Dent Res 79:1604-7
Richardson, J D; Aanonsen, L; Hargreaves, K M (1998) Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J Neurosci 18:451-7
Richardson, J D; Aanonsen, L; Hargreaves, K M (1998) Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 345:145-53
Richardson, J D; Kilo, S; Hargreaves, K M (1998) Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75:111-9
Kilo, S; Harding-Rose, C; Hargreaves, K M et al. (1997) Peripheral CGRP release as a marker for neurogenic inflammation: a model system for the study of neuropeptide secretion in rat paw skin. Pain 73:201-7
Richardson, J D; Aanonsen, L; Hargreaves, K M (1997) SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol 319:R3-4
Ulrich, Y M; Hargreaves, K M; Flores, C M (1997) A comparison of multiple injections versus continuous infusion of nicotine for producing up-regulation of neuronal [3H]-epibatidine binding sites. Neuropharmacology 36:1119-25
Hargreaves, K M; Swift, J Q; Roszkowski, M T et al. (1994) Pharmacology of peripheral neuropeptide and inflammatory mediator release. Oral Surg Oral Med Oral Pathol 78:503-10

Showing the most recent 10 out of 11 publications